Publications by authors named "Marc A Becker"

Claim this Profile
M
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity.
Rachel M Hurley, Jill M Wagner, Arun Kanakkanthara, Annapoorna Venkatachalam, Aaron M Deisinger, Marc A Becker

Exp Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, Cristina Correia, Taylor M Weiskittel, Marc A Becker

NAR Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
Ann L Oberg, Ethan P Heinzen, Xiaonan Hou, Mariam M Al Hilli, Rachel M Hurley, Marc A Becker

Sci Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
Cheyne Kurokawa, Ianko D Iankov, S Keith Anderson, Ileana Aderca, Alexey A Leontovich, Marc A Becker

J Natl Cancer Inst· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.
Kristina A Butler, Xiaonan Hou, Marc A Becker, Valentina Zanfagnin, Sergio Enderica-Gonzalez

Neoplasia· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Mariam M AlHilli, Marc A Becker, S John Weroha, Karen S Flatten, Rachel M Hurley

Gynecol Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Marc A Becker, Xiaonan Hou, Piyawan Tienchaianada, Brian B Haines, Sean C Harrington

BMC Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.
Marc A Becker, Yasir H Ibrahim, Annabell S Oh, Dedra H Fagan, Sara A Byron

PLoS One· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Gretchen Glaser, S John Weroha, Marc A Becker, Xiaonan Hou, Sergio Enderica-Gonzalez

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
Marc A Becker, Paul Haluska, Laurie K Bale, Claus Oxvig, Cheryl A Conover

Mol Cancer Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
S John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, Sean C Harrington, Ann L Oberg

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Marc A Becker, Thahir Farzan, Sean C Harrington, James W Krempski, S John Weroha

Mol Cancer Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.
Clare L Scott, Marc A Becker, Paul Haluska, Goli Samimi

Front Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.
Marc A Becker, Xiaonan Hou, Sean C Harrington, S John Weroha, Sergio E Gonzalez

Clin Cancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.
Marc A Becker, Yasir H Ibrahim, Xiaojiang Cui, Adrian V Lee, Douglas Yee

Mol Endocrinol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis